These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24788656)

  • 21. The association between fluconazole dose and MIC with mortality and persistence in candidemia.
    Ghanem-Zoubi N; Qasum M; Khoury J; Zorbavel D; Arnon M; Geffen Y; Paul M
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1773-1780. PubMed ID: 31197619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Candidaemia in a paediatric centre and importance of central venous catheter removal.
    Karadag-Oncel E; Kara A; Ozsurekci Y; Arikan-Akdagli S; Cengiz AB; Ceyhan M; Gur D; Celik M; Ozkaya-Parlakay A
    Mycoses; 2015 Mar; 58(3):140-8. PubMed ID: 25678411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis.
    González-Lara MF; Torres-González P; Cornejo-Juárez P; Velázquez-Acosta C; Martinez-Gamboa A; Rangel-Cordero A; Bobadilla-Del-Valle M; Ostrosky-Zeichner L; Ponce-de-León A; Sifuentes-Osornio J
    BMC Infect Dis; 2017 Dec; 17(1):753. PubMed ID: 29212442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study.
    Orasch C; Mertz D; Garbino J; van Delden C; Emonet S; Schrenzel J; Zimmerli S; Damonti L; Mühlethaler K; Imhof A; Ruef C; Fehr J; Zbinden R; Boggian K; Bruderer T; Flückiger U; Conen A; Khanna N; Frei R; Bregenzer T; Lamoth F; Erard V; Bochud PY; Calandra T; Bille J; Marchetti O;
    J Infect; 2018 May; 76(5):489-495. PubMed ID: 29378240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
    Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
    J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade.
    Parmeland L; Gazon M; Guerin C; Argaud L; Lehot JJ; Bastien O; Allaouchiche B; Michallet M; Picot S; Bienvenu AL;
    Med Mycol; 2013 Jan; 51(1):33-7. PubMed ID: 22680978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breakthrough candidaemia in the era of broad-spectrum antifungal therapies.
    Cuervo G; Garcia-Vidal C; Nucci M; Puchades F; Fernández-Ruiz M; Obed M; Manzur A; Gudiol C; Pemán J; Aguado JM; Ayats J; Carratalà J
    Clin Microbiol Infect; 2016 Feb; 22(2):181-188. PubMed ID: 26460064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of candidemia cases in a city hospital during the COVID-19 pandemic.
    Ozalp O; Komec S; Unsel M; Gunduz A; Altuntas Aydin O
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2558-2568. PubMed ID: 38567615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of the fluconazole trailing effect on the persistence of Candida albicans bloodstream infection when treated with fluconazole.
    Lin SY; Huang HY; Chang LL; Wang YL; Chen TC; Chang K; Tu HP; Lu PL
    Clin Microbiol Infect; 2024 Jul; 30(7):945-950. PubMed ID: 38527614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
    Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
    Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection.
    Levinson T; Dahan A; Novikov A; Paran Y; Berman J; Ben-Ami R
    Mycoses; 2021 Jan; 64(1):78-85. PubMed ID: 33000505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain.
    Puig-Asensio M; Padilla B; Garnacho-Montero J; Zaragoza O; Aguado JM; Zaragoza R; Montejo M; Muñoz P; Ruiz-Camps I; Cuenca-Estrella M; Almirante B; ; ;
    Clin Microbiol Infect; 2014 Apr; 20(4):O245-54. PubMed ID: 24125548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Age group, geographical incidence and patterns of antifungal susceptibility of Candida species causing candidemia in the Spanish paediatric population].
    García-Rodríguez J; Cantón E; Pemán J; Alvarez M; Ezpeleta G; Gómez-Nieto A; Iglesias I; Martín-Mazuelos E; Ramírez-de Ocariz I; Rezusta A; Royo-García G;
    Enferm Infecc Microbiol Clin; 2013; 31(6):363-8. PubMed ID: 23398860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological features of nosocomial candidaemia in neonates, infants and children: A multicentre study in Iran.
    Ahangarkani F; Shokohi T; Rezai MS; Ilkit M; Mahmoodi Nesheli H; Karami H; Tamaddoni A; Alizadeh-Navaei R; Khodavaisy S; Meis JF; Badali H
    Mycoses; 2020 Apr; 63(4):382-394. PubMed ID: 31985076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia.
    Al Thaqafi AH; Farahat FM; Al Harbi MI; Al Amri AF; Perfect JR
    Int J Infect Dis; 2014 Apr; 21():5-9. PubMed ID: 24468816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Andes D; Diekema DJ; Espinel-Ingroff A; Sheehan D;
    Drug Resist Updat; 2010 Dec; 13(6):180-95. PubMed ID: 21050800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.
    Chen CY; Huang SY; Tsay W; Yao M; Tang JL; Ko BS; Chou WC; Tien HF; Hsueh PR
    Int J Antimicrob Agents; 2012 Dec; 40(6):533-8. PubMed ID: 23006521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan.
    Chen TC; Chen YH; Tsai JJ; Peng CF; Lu PL; Chang K; Hsieh HC; Chen TP
    J Microbiol Immunol Infect; 2005 Jun; 38(3):200-10. PubMed ID: 15986071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and molecular characteristics of bloodstream infections caused by Candida albicans in children from 2003 to 2011.
    Tsai MH; Wang SH; Hsu JF; Lin LC; Chu SM; Huang HR; Chiang MC; Fu RH; Lu JJ; Huang YC
    Clin Microbiol Infect; 2015 Nov; 21(11):1018.e1-8. PubMed ID: 26148466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation.
    Farmakiotis D; Kyvernitakis A; Tarrand JJ; Kontoyiannis DP
    Clin Microbiol Infect; 2015 Jan; 21(1):79-86. PubMed ID: 25636931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.